# Clinical developments in obesity and diabetes medications > Live situation record from CLSTR: https://clstr.news/situations/clinical-developments-in-obesity-and-diabetes-medications > Updated: 2026-10-07T17:31:28.000Z. Sources: 12. Developments: 2. Pharmaceutical developments regarding experimental treatments for obesity and type 2 diabetes have shown positive results in Phase II clinical trials. In late September 2026, Roche and Genentech reported successful Phase II results for enicepatide, a once-weekly dual GLP-1/GIP receptor agonist. At a 24 mg dose, participants saw a mean weight loss of 15.5% over 48 weeks and significant improvements in glycemic control. Roche intends to move the drug into Phase III studies. By early October 2026, Zealand Pharma reported that its amylin-mimicking therapy, petrelintide, met primary endpoints in a Phase 2 study. Patients receiving once-weekly doses experienced weight loss between 7.4% and 9.2% over 28 weeks, alongside improvements in HbA1c levels. Zealand Pharma is developing this therapy in collaboration with Roche, and the two companies have transitioned to late-stage testing involving approximately 7,000 participants. ## Timeline ### 2026-10-07: Zealand Pharma reports positive Phase 2 results for obesity drug petrelintide Zealand Pharma's Phase 2 trial of petrelintide showed weight loss of up to 9.2% in adults with obesity and type 2 diabetes, meeting its primary endpoint alongside improved blood sugar control. 3 sources. https://clstr.news/cluster/zealand-pharma-reports-positive-phase-2-results-for-obesity-drug-petrelintide ### 2026-09-22: Roche reports positive Phase II results for obesity and diabetes drug enicepatide Roche's experimental drug enicepatide showed significant success in Phase II trials, reducing average weight by 15.5% and substantially lowering HbA1c levels in adults with type 2 diabetes. 9 sources. https://clstr.news/cluster/roche-reports-positive-phase-ii-results-for-weight-loss-drug-enicepatide --- Cite as: Clinical developments in obesity and diabetes medications. CLSTR, https://clstr.news/situations/clinical-developments-in-obesity-and-diabetes-medications